Lung cancer is one of the leading causes of death in the United States. The two major types of lung cancer are small cell lung cancer and non–small cell lung cancer (NSCLC); NSCLC is more common. Screening and prevention rates for lung cancer are poor compared with those for other types of cancer, but have improved in the past couple of years because of recent updates to lung cancer screening guidelines. Treatment varies depending upon the disease stage. The emergence of newer oral agents such as afatinib, crizotinib, nivolumab, and ceritinib has contributed immensely to lung cancer treatment. It is important for pharmacists to stay up-to-date on treatment agents in order to promote patients’ well-being.